Lyme Disease vaccine candidate enters Phase 2 clinical development
by Press Release from Outbreak News Today on (#455GM)
In a follow-up on the development of Valneva's Lyme Disease vaccine candidate, VLA15, the company announced today that it is entering Phase 2 Clinical Development. The overall Phase 2 objective for VLA15 is to determine the optimal dosage level and schedule for use in Phase 3 pivotal field efficacy studies, based on immunogenicity and safety data The Phase ["]
The post Lyme Disease vaccine candidate enters Phase 2 clinical development appeared first on Outbreak News Today.